Quanterix Corporation Business Acquisition, Pro Forma Revenue
Quanterix Corporation (QTRX) reported Business Acquisition, Pro Forma Revenue of $174.27 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2026-03-02
- Quanterix Corporation business acquisition, pro forma revenue for the quarter ending 2025-12-31 was $42.77M, a 21.27% decline year-over-year.
- Quanterix Corporation business acquisition, pro forma revenue for the quarter ending 2025-09-30 was $41.07M, a 24.67% decline year-over-year.
- Quanterix Corporation business acquisition, pro forma revenue for the quarter ending 2024-12-31 was $54.33M.
- Quanterix Corporation business acquisition, pro forma revenue for the quarter ending 2024-09-30 was $54.52M.
- Quanterix Corporation business acquisition, pro forma revenue for fiscal 2025 was $174.27M, a 19.37% decline from fiscal 2024.
- Quanterix Corporation business acquisition, pro forma revenue for fiscal 2024 was $216.15M.
- Quanterix Corporation business acquisition, pro forma revenue for fiscal 2019 was $57.60M, a 48.63% increase from fiscal 2018.
- Quanterix Corporation business acquisition, pro forma revenue for fiscal 2018 was $38.75M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2025-12-31 | $42.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $83.85M derived: sum of 2 quarters · filed 2026-03-02 | $174.27M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $41.07M 10-Q · filed 2025-11-10 | $131.49M 10-Q · filed 2025-11-10 | ||
| 2024-12-31 | $54.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $108.85M derived: sum of 2 quarters · filed 2026-03-02 | $216.15M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $54.52M 10-Q · filed 2025-11-10 | $161.81M 10-Q · filed 2025-11-10 | ||
| 2019-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $30.86M derived: sum of 2 quarters · filed 2022-03-01 | $44.64M derived: sum of 3 quarters · filed 2022-03-01 | $57.60M 10-K · filed 2022-03-01 |
| 2019-09-30 | $14.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $28.63M derived: sum of 2 quarters · filed 2020-11-06 | $41.59M 10-Q · filed 2020-11-06 | $52.72M derived: sum of 4 quarters · filed 2021-03-05 |
| 2019-06-30 | $13.78M 10-Q · filed 2020-08-04 | $26.73M 10-Q · filed 2020-08-04 | $37.86M derived: sum of 3 quarters · filed 2021-03-05 | $48.65M derived: sum of 4 quarters · filed 2021-03-05 |
| 2019-03-31 | $12.91M 10-Q · filed 2020-05-07 | $24.09M derived: sum of 2 quarters · filed 2021-03-05 | $34.87M derived: sum of 3 quarters · filed 2021-03-05 | |
| 2018-12-31 | $11.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $21.97M derived: sum of 2 quarters · filed 2021-03-05 | $38.75M 10-K · filed 2021-03-05 | |
| 2018-09-30 | $10.79M 10-Q · filed 2019-11-08 | $27.57M 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |